Novo Holdings

Novo Holdings, established in 1999, is the holding company of the Novo Group, primarily managing the investment assets of the Novo Nordisk Foundation. Based in Copenhagen, with additional offices in San Francisco and Boston, Novo Holdings focuses on two main investment categories: Life Science Investments, which encompasses funding life science companies at various stages of development, and Financial Investments, which entails managing a diversified portfolio of equity and fixed income securities. As a prominent life science investor, Novo Holdings aims to create long-term value while ensuring that the Foundation can distribute returns for scientific, social, and humanitarian purposes to enhance public health and welfare. The company has also developed initiatives such as Novo Seeds, which supports early-stage applied research in life sciences, and invests in later-stage life science companies through growth equity. Novo Holdings maintains a strategic influence over affiliated companies, aligning their operations with the values and objectives of the Novo Group.

Scott Beardsley

Managing Partner, Life Sciences Operating Committee, Venture Investments

Jørgen Boe

Director

Emmanuelle Coutanceau

Partner

Thomas P. Dyrberg

Partner

Anna Fan

Senior Partner, Life Sciences Operating Committee, Venture Investments, Venture Investments (US) Inc.

Casper Tind Hansen

Principal

Karen Hong

Partner

Junie Lim

DIRECTOR, GENERAL COUNSEL (US)

Heather Ludvigsen

Investor

Peter Moldt

Partner

Søren Møller

Managing Partner

Lone Penby

Venture Coordinator

Jørgen Søberg Petersen

Senior Partner, Seed Investments

Eric M. Snyder

Principal

Past deals in Africa

Engimmune Therapeutics

Seed Round in 2022
Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences engineering highly potent and specific therapies based on T cell receptors (TCR) targeting solid tumors.

Freeline

Series C in 2020
Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.

Sonion

Acquisition in 2014
Sonion A/S design and manufacturing of advanced miniature components and solutions.